0001209191-21-044959.txt : 20210702
0001209191-21-044959.hdr.sgml : 20210702
20210702162152
ACCESSION NUMBER: 0001209191-21-044959
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210630
FILED AS OF DATE: 20210702
DATE AS OF CHANGE: 20210702
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Stoppel Laura
CENTRAL INDEX KEY: 0001865119
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40551
FILM NUMBER: 211070405
MAIL ADDRESS:
STREET 1: C/O ACUMEN PHARMACEUTICALS, INC.
STREET 2: 427 PARK STREET
CITY: CHARLOTTESVILLE
STATE: VA
ZIP: 22902
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Acumen Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001576885
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 364108129
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4435 NORTH FIRST STREET, SUITE 360
CITY: LIVERMORE
STATE: CA
ZIP: 94551
BUSINESS PHONE: 925-368-8508
MAIL ADDRESS:
STREET 1: 4435 NORTH FIRST STREET, SUITE 360
CITY: LIVERMORE
STATE: CA
ZIP: 94551
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-06-30
0
0001576885
Acumen Pharmaceuticals, Inc.
ABOS
0001865119
Stoppel Laura
C/O RA CAPITAL MANAGEMENT
200 BERKELEY STREET, 18TH FLOOR
BOSTON
MA
02116
1
0
0
0
Stock Option (Right to Buy)
16.00
2021-06-30
4
A
0
34000
0.00
A
2031-06-30
Common Stock
34000
34000
D
The shares subject to the option will vest in equal monthly installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Reporting Person's continuous service through each such vesting date and shall vest and become immediately exercisable prior to the effectiveness of a change in control.
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
/s/ Katherine Denby, Attorney-in-Fact
2021-07-02